- Hemostemix (HEM) has closed the second tranche of its previously announced non-brokered private placement of units for gross proceeds of $1,364,710.10
- The company issued a total of 4,549,034 units for $0.30 per unit
- Proceeds from the offering will be used primarily to fund the buildout and production of ACP-01
- Hemostemix is an autologous stem cell therapy company
- Shares of Hemostemix Inc. (HEM) opened trading at C$0.33
Hemostemix (HEM) has closed the second tranche of a non-brokered private placement of units for gross proceeds of $1,364,710.10.
The company issued a total of 4,549,034 units for $0.30 per unit. Each unit consists of one common share and one common share purchase warrant. Each warrant entitles the holder to acquire one additional share for a period of 24 months.
Warrants are subject to an acceleration clause.
Hemostemix paid cash fees of approximately $93,176.80 and issued 310,589 options to eligible finders.
Proceeds from the offering will be used to pay finder fees, filing and regulatory fees, debt reduction and commencing the buildout and production of ACP-01.
All securities issued will be subject to a four-month hold period.
Hemostemix is an autologous stem cell therapy company. The company has developed and is commercializing its lead product ACP-01 for the treatment of CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and other conditions of ischemia.
Shares of Hemostemix Inc. (HEM) opened trading at C$0.33.
